Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Uprichard

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Journal of Hepatology|February 25, 2016
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvirHarel Dahari, Laetitia Canini, Frederik Graw, et al.
Antiviral Research|June 28, 2020
Modeling based response guided therapy in subjects with recent hepatitis C infectionEvan Gorstein, Marianne Martinello, Alexander Churkin, et al.
Hepatology Communications|February 7, 2018
Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infectionLaetitia Canini, Christopher Koh, Scott J Cotler, et al.
Plos Computational Biology|August 3, 2023
Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kineticsAtesmachew Hailegiorgis, Yuji Ishida, Nicholson Collier, et al.
Elife|November 3, 2021
Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearanceLouis Shekhtman, Miquel Navasa, Natasha Sansone, et al.
Antiviral Research|February 4, 2019
A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis CChristopher Koh, Preeti Dubey, Ma Ai Thanda Han, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 1, 2018
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosisMartina Gambato, Laetitia Canini, Sabela Lens, et al.
Scientific Reports|October 21, 2020
Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot studyOhad Etzion, Harel Dahari, David Yardeni, et al.
The Lancet. Infectious Diseases|July 21, 2015
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Laetitia Canini, Harel Dahari, et al.
Viruses|February 26, 2022
Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced IndividualsSusan L Uprichard, Amornrat O'Brien, Monika Evdokimova, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Journal of Hepatology|February 25, 2016
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvirHarel Dahari, Laetitia Canini, Frederik Graw, et al.
Antiviral Research|June 28, 2020
Modeling based response guided therapy in subjects with recent hepatitis C infectionEvan Gorstein, Marianne Martinello, Alexander Churkin, et al.
Hepatology Communications|February 7, 2018
Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infectionLaetitia Canini, Christopher Koh, Scott J Cotler, et al.
Plos Computational Biology|August 3, 2023
Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kineticsAtesmachew Hailegiorgis, Yuji Ishida, Nicholson Collier, et al.
Elife|November 3, 2021
Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearanceLouis Shekhtman, Miquel Navasa, Natasha Sansone, et al.
Antiviral Research|February 4, 2019
A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis CChristopher Koh, Preeti Dubey, Ma Ai Thanda Han, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 1, 2018
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosisMartina Gambato, Laetitia Canini, Sabela Lens, et al.
Scientific Reports|October 21, 2020
Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot studyOhad Etzion, Harel Dahari, David Yardeni, et al.
The Lancet. Infectious Diseases|July 21, 2015
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Laetitia Canini, Harel Dahari, et al.
Viruses|February 26, 2022
Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced IndividualsSusan L Uprichard, Amornrat O'Brien, Monika Evdokimova, et al.
Pageof 6